Thymic Involution Destroys Adaptive Immunity with No Proven Reversal Strategy

The thymus — the organ that trains new immune cells — shrinks dramatically after puberty, losing 90%+ of functional tissue by age 50. Old people cannot mount effective immune responses to new infections or vaccines. Greg Fahy's TRIIM trial (N=9) showed partial thymic regeneration, but no properly powered trial has confirmed this.

By age 60, naive T-cell output drops to <5% of young adult levels. The remaining repertoire becomes oligoclonal. Fahy's TRIIM trial (growth hormone + DHEA + metformin) showed partial thymic regeneration on MRI with epigenetic age reversal, but N=9 with no control group. IL-7 therapy expands T-cells but bypasses the thymus. Sex steroid ablation regrows thymus temporarily but is impractical. Engineered thymic organoids are promising in mice but nowhere near human use.

Why It Matters

COVID-19 mortality was ~100x higher in 80+ vs under 40, primarily due to immunosenescence. Flu kills 36,000+ Americans annually (>90% of deaths in 65+). Vaccine efficacy drops from 40-60% in adults to 10-30% in elderly. Economic burden estimated at $100B+ annually in the US.

Startup Approach

Run properly powered TRIIM replication trial with immune function endpoints. Or engineer thymic organoids from patient iPSCs, implanted subcutaneously as 'auxiliary thymus.' Start with immunocompromised patients (post-chemo, DiGeorge), then expand to age-related decline.

NIH Funding

NIA and NIAID co-fund immunosenescence research. COVID-19 pandemic massively increased funding. NIH Reporter: 150+ active grants on immunosenescence/thymic involution.

Who's Working On It

Intervene Immune (Greg Fahy, TRIIM-X trials), Marcel van den Brink (MSK, thymic regeneration post-BMT), NIA Intramural Research Program